This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Inflammation and Obesity-associated Disease (Adipo...
Clinical trial

Inflammation and Obesity-associated Disease (Adipos2)

Read time: 1 mins
Last updated:1st Dec 2014

Visceral obesity and adipose inflammation is considered a driving force of obesity-related systemic disease, e.g. liver cirrhosis and chronic kidney disease (CKD). Inflammatory resolution is actively regulated by specialized pro-resolving mediators (SPMs), including the endogenous eicosanoid LXA4. Impairment of SPMs may underlie development of obesity-related pathology.We hypothesize that obese patients who develop obesity-related liver and kidney disease do so because they suffer from impaired endogenous production of pro-resolving lipids. This will result in aggravated adipose inflammation, which causes systemic pathologies such as kidney disease. We thus wish to investigate adipose inflammation and the pro-resolving lipid profile of obese subjects with and without CKD and liver disease. We also aim to investigate whether LXA4 can alter the phenotype of human adipose macrophages ex vivo.


Study Type: Observational
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Inflammation and Obesity-associated Disease
Estimated Enrollment: 80
Study Start Date: December 2014
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)

Category Value
Study start date 2014-12-01

View full details